Evidence network for deaths_(OS)

1IMpassion-132 (PD-L1 positive population), 20246KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019 KEYNOTE-119 (PD-L1 CPS of 1 or more) DUPLICATE, 2019 KEYNOTE-119 (PD-L1 CPS of 10 or more), 2019 KEYNOTE-119 (PD-L1 positive CPS = 10 or more), 2019 KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 2019Standard of Care (SoC)carboplatingemcitabinepembrolizumab aloneatezolizumab based treatmentdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)carboplatingemcitabinepembrolizumab aloneatezolizumab based treatment
Standard of Care (SoC)---NANANANA
carboplatinNA---NANANA
gemcitabineNANA---NANA
pembrolizumab aloneNANANA---NA
atezolizumab based treatmentNANANANA---

pathologies: 240 - treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866 result logic